The presence of RAS mutations and RAS pathway activation in lung cancer was previously shown to confer the highest sensitivity to MEK inhibitors among a panel of 500 oncology drugs (55), demonstrating that RAS mutations may be indicators of sensitivity to MEK inhibitors. The gene discussed is MAP2K7; the disease is lung carcinoma.